Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Nikolai Anton Sopko · EVINCIS BIO, INC. · 2021 · $314,913 — Abstract Erectile dysfunction (ED) affects about 18 million men in the U.S. and is estimated to affect 322 million men worldwide by 2025. ED can have a profound negative impact on quality of life and well-being and is often associated with anxiety and depression. ED also represents a significant eco…
Richard B Kennedy · MAYO CLINIC ROCHESTER · 2021 · $783,307 — PROJECT SUMMARY/ABSTRACT This application is a request for funding of a research program focused on understanding the factors associated with waning immune response to mumps vaccine. Waning immunity to mumps is a public health concern and a major obstacle in the control and elimination of mumps dise…
Milka Koupenova · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2021 · $418,750 — PROJECT SUMMARY Influenza infection increases the incidence of acute MI (AMI) within the first 7 days after detection and the therapeutic benefit of vaccination is comparable to current therapies for secondary prevention of AMI. Platelets are the blood component central to thrombosis and uncontroll…
RONALD LEVY · STANFORD UNIVERSITY · 2021 · $522,472 — Project Summary: Cancer is a leading global cause of mortality. The goal of this multi-disciplinary project is to pre-clinically advance a novel concept for selective and efficient mRNA delivery that enables a highly promising vaccination strategy for cancer immunotherapy. Given the potential of can…
Hiten D Madhani · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $636,859 — Objective: We propose to construct and distribute a series of SARS-CoV-2-derived molecular clones using powerful genome assembly and rapid CRISPR-based manipulation methods available in the yeast Saccharomyces cerevisiae. We will develop and apply methods to mutate and tag each of the 18 viral prote…
Wyatt ALLEN MILLER · IOWA STATE UNIVERSITY · 2021 · $174,750 — Flaviviruses include many serious pathogens such as Zika, dengue, West Nile, and yellow fever viruses. In infected cells these viruses produce abundant, noncoding, short flavivirus RNAs (sfRNAs) that comprise most of the ~500 nucleotide 3’ untranslated region of the viral genome. These novel viral R…
Luis J Sigal · THOMAS JEFFERSON UNIVERSITY · 2021 · $234,000 — Summary Prevention of morbidity and mortality from viral infections and of complications from live-virus vaccine immunizations requires the identification of genes that confer natural resistance to viruses. Ectromelia virus (ECTV), the agent of mousepox, is a natural pathogen of the mouse. When ECT…
Zachary Scott Morris · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $765,000 — ABSTRACT We are developing a combined modality therapeutic approach to eradicating metastatic cancers that are immunologically “cold” and do not respond to immune checkpoint inhibition (ICI). Using an “in situ vaccine” regimen consisting of 12 Gy focal external beam radiation therapy (EBRT) and int…
Norbert Pardi · UNIVERSITY OF PENNSYLVANIA · 2021 · $633,178 — ABSTRACT Vaccines prevent hundreds of millions of illnesses and save millions of lives every year. Various types of licensed vaccines (live attenuated and inactivated pathogens, adjuvanted protein subunits) provide some level of protection against a variety of dangerous illnesses. However, there are…
EVAN J ANDERSON · EMORY UNIVERSITY · 2021 · $669,970 — Summary/Abstract The Emory VTEU has proven essential in the fight against the pandemic. This supplement will allow for further investigations into second generation vaccines trials (20-0034). 1…
Michael S Diamond · WASHINGTON UNIVERSITY · 2021 · $953,281 — PROJET SUMMARY/ABSTRACT Globally, the four serotypes of DENV cause an estimated 390 million new cases of dengue fever and 500,000 cases of dengue hemorrhagic fever (DHF) per year. Zika virus (ZIKV) is a related emerging virus linked to Guillain-Barre syndrome in adults, and microcephaly, congenital …
Ronald G Collman · UNIVERSITY OF PENNSYLVANIA · 2021 · $4,014,123 — CFAR Overview ABSTRACT This competing renewal application for the Penn Center for AIDS Research (CFAR) builds on an outstanding record of dynamic scientific leadership, organizational structure, resources and infrastructure that advance HIV/AIDS research across the integrated campus of the Universit…
JEANNE ANN JORDAN · GEORGE WASHINGTON UNIVERSITY · 2021 · $359,399 — ABSTRACT Human papillomavirus (HPV) infections are highly prevalent in men and women. High-risk (HR) HPV types 16 & 18 (HPV16/18) are responsible for ~90% of all anal cancers, whose incidence has risen by 96% in the last 2- 3 decades primarily because of the HIV/AIDS epidemic. Indeed, HIV-infected m…
Richard B Kennedy · MAYO CLINIC ROCHESTER · 2021 · $782,918 — ABSTRACT The broad long-term goal of this application is to identify innate and T helper (Th) cell transcriptomic signatures of immune response and further our understanding of sex-dependent human immune responses to two unique influenza A/H3N2 vaccines in a population of older adult males and femal…
Jianrong Li · OHIO STATE UNIVERSITY · 2021 · $469,386 — Abstract This application is to renew a grant to study RNA methylation in pneumoviruses. Pneumoviridae is a new virus family, created in 2016 by elevating the paramyxoviral subfamily Pneumovirinae to family status. The Pneumoviridae family includes two medically important pathogens, human respirator…
Thomas R Hawn · UNIVERSITY OF WASHINGTON · 2021 · $177,373 — Despite the discovery of Mycobacterium tuberculosis (Mtb) over 100 years ago and the availability of effective drugs for over 60 years, there remain formidable hurdles for controlling tuberculosis (TB) disease including the lack of a highly efficacious vaccine, long drug treatment regimens, preventi…
Isaac Jonathan Krauss · BRANDEIS UNIVERSITY · 2021 · $560,769 — Project Summary/Abstract Extensive study of HIV+ individuals in recent years has brought to light many examples of antibodies that can neutralize a broad range of HIV strains and protect against viral challenge in animal models of infection. The portion of viral surface most commonly targeted by suc…
Jilian R Melamed · CARNEGIE-MELLON UNIVERSITY · 2021 · $66,390 — While gene therapy with mRNA offers tremendous potential to transform the management of genetic diseases, delivering mRNA outside the reticuloendothelial system (e.g. liver and spleen) remains challenging. Without carriers that can reach organs such as the lungs, heart, brain, or pancreas, the poten…
Michael Gerner · UNIVERSITY OF WASHINGTON · 2021 · $441,250 — The innate and adaptive arms of the immune system are integrally linked, with dendritic cells (DCs), innate antigen presenting cells, providing critical instructions to elicit the generation of adaptive T cell immunity. Using a novel analytical imaging approach, we recently uncovered that different …
Ronald Goldstein · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 · $184,530 — Abstract As highlighted in PA-19-237, there is a gap in knowledge about non-coding RNAs and their functions for many pathogens, and the human herpesvirus Varicella Zoster Virus (VZV) is one such pathogen. VZV is one of only two of nine human herpesviruses in which microRNAs have not been reported. …